<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577093</url>
  </required_header>
  <id_info>
    <org_study_id>miR-494</org_study_id>
    <nct_id>NCT03577093</nct_id>
  </id_info>
  <brief_title>Molecular Mechanisms of microRNA-494 Involving in Cerebral Ischemia</brief_title>
  <official_title>Study on the Molecular Mechanism of miR-494 Mediating Cell Cycle Regulation Following Cerebral Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We and other investigations suggested that the activation of nerve cell cycle following
      cerebral ischemia led to neuronal apoptosis, glial cell proliferation and the formation of
      glial scar.The cyclin-dependent kinases (CDKs) and cyclins jointly promoted the cell cycle
      progression. Our preliminary clinical trial found a new microRNA-miR-494, which involved in
      the occurrence of acute ischemic stroke. In our animal experiment, miR-494 could relieve
      cerebral ischemia injury through inhibiting cyclin-dependent kinase 6(CDK6),
      ubiquitin-conjugating enzyme E2L6 (UBE2L6) and histone deacetylase 3 (HDAC3), which suggested
      that miR-494 might play an important role in the regulation of cell cycle following cerebral
      ischemia. This project intends to verify the following hypothesis：①miR-494 suppresses CDK6,
      and/or fibroblast growth factor16(FGF16)-Ras-extracellular signal-regulated
      kinase(ERK)--v-myc avian myelocytomatosis viral oncogene homolog(MYC) pathway, and/or
      phosphatase and tensin homolog(PTEN)-/protein kinase B(AKT)-mechanistic target of
      rapamycin(mTOR)-S6k pathway;②miR-494 inhibits UBE2L6, upregulates the hypoxia-inducible
      factor 1 α(HIF-1α) expression in nerve cells, thereby increases the p21 and p27 protein
      levels and inhibits cyclin-dependent kinase2(CDK2)activity;③miR-494 represses HDAC3 and
      downregulates the cyclin-dependent kinase1(CDK1)protein level. These all mediate the cell
      cycle arrest of neurons and astrocytes, reduce the neuronal apoptosis and glial scar
      formation,promote the recovery of neurological function and provide new targets for the
      treatment of ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the molecular mechanism of miR-494 mediating cell cycle regulation following cerebral ischemia</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>ischemic stroke</arm_group_label>
    <description>acute ischemic stroke patients within 6h after stroke onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention at all.</intervention_name>
    <description>There is no intervention at all.</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>ischemic stroke</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        acute ischemic stroke patients who were presented within 6h of the event would be recruited
        to this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1）diagnosis of first ischemic stroke based on clinical information and magnetic
             resonance imaging; (2)presentation of subjects within 6h of the event; (3)National
             Institutes of Health Stroke Scale (NIHSS) score between 4 and 15.

        Exclusion Criteria:

          -  (1）suspected cardiogenic embolism;(2）secondary stroke from cerebral hemorrhage,
             trauma, cancer or aneurysm and so on;(3）bleeding tendency;(4）severe
             cardiac,pulmonary,hepatic or renal insufficiency;(5）Vital signs are unstable to be
             assessed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Luo Yumin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luo Yumin</last_name>
    <phone>01083198129</phone>
    <email>yumin111@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luo Yumin</last_name>
      <phone>01083198129</phone>
      <email>yumin111@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bizen N, Inoue T, Shimizu T, Tabu K, Kagawa T, Taga T. A growth-promoting signaling component cyclin D1 in neural stem cells has antiastrogliogenic function to execute self-renewal. Stem Cells. 2014 Jun;32(6):1602-15. doi: 10.1002/stem.1613.</citation>
    <PMID>24302516</PMID>
  </reference>
  <reference>
    <citation>Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, Tao Z, Xu C, Song J, Ji X, Luo Y. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke. 2013 Jun;44(6):1706-13. doi: 10.1161/STROKEAHA.111.000504. Epub 2013 Apr 23.</citation>
    <PMID>23613494</PMID>
  </reference>
  <results_reference>
    <citation>Iyirhiaro GO, Zhang Y, Estey C, O'Hare MJ, Safarpour F, Parsanejad M, Wang S, Abdel-Messih E, Callaghan SM, During MJ, Slack RS, Park DS. Regulation of ischemic neuronal death by E2F4-p130 protein complexes. J Biol Chem. 2014 Jun 27;289(26):18202-13. doi: 10.1074/jbc.M114.574145. Epub 2014 May 14.</citation>
    <PMID>24828495</PMID>
  </results_reference>
  <results_reference>
    <citation>Nobs L, Baranek C, Nestel S, Kulik A, Kapfhammer J, Nitsch C, Atanasoski S. Stage-specific requirement for cyclin D1 in glial progenitor cells of the cerebral cortex. Glia. 2014 May;62(5):829-39. doi: 10.1002/glia.22646. Epub 2014 Feb 19.</citation>
    <PMID>24550001</PMID>
  </results_reference>
  <results_reference>
    <citation>Demyanenko S, Uzdensky A. Profiling of Signaling Proteins in Penumbra After Focal Photothrombotic Infarct in the Rat Brain Cortex. Mol Neurobiol. 2017 Nov;54(9):6839-6856. doi: 10.1007/s12035-016-0191-x. Epub 2016 Oct 22.</citation>
    <PMID>27771897</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao H, Luo Y, Liu X, Wang R, Yan F, Liu X, Li S, Leak RK, Ji X. Ischemic post-conditioning partially reverses cell cycle reactivity following ischemia/reperfusion injury: a genome-wide survey. CNS Neurol Disord Drug Targets. 2013 May 1;12(3):350-9.</citation>
    <PMID>23469856</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu L, Lu Y, Martinez J, Bi Y, Lian G, Wang T, Milasta S, Wang J, Yang M, Liu G, Green DR, Wang R. Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1α-dependent. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1564-9. doi: 10.1073/pnas.1518000113. Epub 2016 Jan 25.</citation>
    <PMID>26811453</PMID>
  </results_reference>
  <results_reference>
    <citation>Fournier M, Orpinell M, Grauffel C, Scheer E, Garnier JM, Ye T, Chavant V, Joint M, Esashi F, Dejaegere A, Gönczy P, Tora L. KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification. Nat Commun. 2016 Oct 31;7:13227. doi: 10.1038/ncomms13227.</citation>
    <PMID>27796307</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang Y, Hsieh J. HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13541-6. doi: 10.1073/pnas.1411939111. Epub 2014 Aug 26.</citation>
    <PMID>25161285</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Vice President of Xuanwu Hospital,Capital Medical University</investigator_title>
  </responsible_party>
  <keyword>stroke, miR-494, neuroprotection, CDK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data for all primary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent panel.Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
    <ipd_url>http://bethesda.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

